Cargando…

Advanced development of biomarkers for immunotherapy in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is the most common liver cancer and one of the leading causes of cancer-related deaths in the world. Mono-immunotherapy and combination therapy with immune checkpoint inhibitors (ICIs) and multitargeted tyrosine kinase inhibitors (TKIs) or anti-vascular endothelial gro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peng, Xuenan, Gong, Caifeng, Zhang, Wen, Zhou, Aiping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885011/ https://www.ncbi.nlm.nih.gov/pubmed/36727075 http://dx.doi.org/10.3389/fonc.2022.1091088

Ejemplares similares

Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy
por: He, Yuqing, et al.
Publicado: (2021)

Phosphogluconate dehydrogenase is a predictive biomarker for immunotherapy in hepatocellular carcinoma
por: Liu, Tiantian, et al.
Publicado: (2022)

Editorial: Biomarkers of Immune-Checkpoint-Inhibitor Immunotherapies in Hepatocellular Carcinomas
por: Guo, Zhanjun, et al.
Publicado: (2022)

Serum Concentration of CD137 and Tumor Infiltration by M1 Macrophages Predict the Response to Sintilimab plus Bevacizumab Biosimilar in Advanced Hepatocellular Carcinoma Patients
por: Zhang, Wen, et al.
Publicado: (2022)

Application of Immunotherapy in Hepatocellular Carcinoma
por: Miao, Lele, et al.
Publicado: (2021)

Editorial: Immunotherapy in Hepatocellular Carcinoma
por: Li, Bin, et al.
Publicado: (2021)

ZCCHC17 Served as a Predictive Biomarker for Prognosis and Immunotherapy in Hepatocellular Carcinoma
por: Liu, Fahui, et al.
Publicado: (2022)

Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?
por: Rizzo, Alessandro, et al.
Publicado: (2021)

Efficacy of Sorafenib Combined With Immunotherapy Following Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma: A Propensity Score Analysis
por: Qin, Jian, et al.
Publicado: (2022)

Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects
por: Zhong, Cheng, et al.
Publicado: (2021)

Advanced lung cancer inflammation index predicts survival outcomes of hepatocellular carcinoma patients receiving immunotherapy
por: Li, Qian, et al.
Publicado: (2023)

Circulating immune index predicting the prognosis of patients with hepatocellular carcinoma treated with lenvatinib and immunotherapy
por: Guo, De-Zhen, et al.
Publicado: (2023)

Cuproptosis-related genes score: A predictor for hepatocellular carcinoma prognosis, immunotherapy efficacy, and metabolic reprogramming
por: Nie, Guilin, et al.
Publicado: (2023)

Molecular targeted therapy and immunotherapy in advanced hepatocellular carcinoma: a systematic review and Bayesian network meta-analysis based on randomized controlled trials
por: Zhang, Yun-Long, et al.
Publicado: (2023)

Research progress of targeted therapy combined with immunotherapy for hepatocellular carcinoma
por: Xie, Shuqi, et al.
Publicado: (2023)

Peripheral Blood Genetic Biomarkers for the Early Diagnosis of Hepatocellular Carcinoma
por: Song, Ting, et al.
Publicado: (2021)

SP70 is a novel biomarker of hepatocellular carcinoma
por: Wang, Lin, et al.
Publicado: (2023)

Immunotherapy Updates in Advanced Hepatocellular Carcinoma
por: Singh, Amisha, et al.
Publicado: (2021)

ELOVLs Predict Distinct Prognosis Value and Immunotherapy Efficacy In Patients With Hepatocellular Carcinoma
por: Zhang, Yu, et al.
Publicado: (2022)

Immunotherapies for advanced hepatocellular carcinoma
por: Sun, Li-Yang, et al.
Publicado: (2023)

The Role of TIM-3 in Hepatocellular Carcinoma: A Promising Target for Immunotherapy?
por: Ganjalikhani Hakemi, Mazdak, et al.
Publicado: (2020)

AGTRAP Is a Prognostic Biomarker Correlated With Immune Infiltration in Hepatocellular Carcinoma
por: Liu, Shanshan, et al.
Publicado: (2021)

Advances of Targeted Therapy for Hepatocellular Carcinoma
por: Niu, Mengke, et al.
Publicado: (2021)

Myosteatosis can Predict Unfavorable Outcomes in Advanced Hepatocellular Carcinoma Patients Treated With Hepatic Artery Infusion Chemotherapy and Anti-PD-1 Immunotherapy
por: Yi, Xiaoping, et al.
Publicado: (2022)

Identification and Validation of Novel Biomarkers for Diagnosis and Prognosis of Hepatocellular Carcinoma
por: Hu, Xiaoyi, et al.
Publicado: (2020)

A Novel Nine-lncRNA Risk Signature Correlates With Immunotherapy in Hepatocellular Carcinoma
por: Nie, Ye, et al.
Publicado: (2021)

Identification and Validation of TYMS as a Potential Biomarker for Risk of Metastasis Development in Hepatocellular Carcinoma
por: Li, Shuai, et al.
Publicado: (2021)

Advances in Immunotherapy for Hepatocellular Carcinoma
por: Hagiwara, Satoru, et al.
Publicado: (2023)

Advances in immunotherapy for hepatocellular carcinoma
por: Sangro, Bruno, et al.
Publicado: (2021)

Research progress of abnormal lactate metabolism and lactate modification in immunotherapy of hepatocellular carcinoma
por: Xu, Yiwei, et al.
Publicado: (2023)

Computational Characterizing Necroptosis Reveals Implications for Immune Infiltration and Immunotherapy of Hepatocellular Carcinoma
por: Zhu, Jun, et al.
Publicado: (2022)

Combined Stereotactic Body Radiotherapy and Immunotherapy Versus Transarterial Chemoembolization in Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
por: Chiang, Chi-Leung, et al.
Publicado: (2021)

New Blood Biomarkers for the Diagnosis of AFP-Negative Hepatocellular Carcinoma
por: Wang, Ting, et al.
Publicado: (2020)

Identification of Key Genes in Purine Metabolism as Prognostic Biomarker for Hepatocellular Carcinoma
por: Su, Wen-Jing, et al.
Publicado: (2021)

Mouse Models of Hepatocellular Carcinoma: Classification, Advancement, and Application
por: Liu, Sha, et al.
Publicado: (2022)

Corrigendum: Identification and Validation of Novel Biomarkers for Diagnosis and Prognosis of Hepatocellular Carcinoma
por: Hu, Xiaoyi, et al.
Publicado: (2020)

An Integrative Analysis Reveals the Underlying Association Between CTNNB1 Mutation and Immunotherapy in Hepatocellular Carcinoma
por: Mo, Zhuomao, et al.
Publicado: (2020)

Liquid biopsy to identify biomarkers for immunotherapy in hepatocellular carcinoma
por: Ao, Huang, et al.
Publicado: (2021)

Biomarkers for Immunotherapy of Oral Squamous Cell Carcinoma: Current Status and Challenges
por: Almangush, Alhadi, et al.
Publicado: (2021)

CEUS and CT/MRI LI-RADS in Association With Serum Biomarkers for Differentiation of Combined Hepatocellular-Cholangiocarcinoma From Hepatocellular Carcinoma
por: Zhou, Yan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ndt8102na6prm3ej1o5h4mms78